Long-term follow-up data from the phase III KATHERINE study in people with HER2-positive early-stage breast cancer who have residual invasive disease following neoadjuvant treatment showed that a statistically significant and clinically meaningful improvement in overall survival, a secondary endpoint, was observed with adjuvant Kadcyla (ado-trastuzumab emtansine) compared to Herceptin (trastuzumab).
In 1991, the National Breast Cancer Coalition demanded that the federal government spend $300 million more on breast cancer research. This push resulted in the creation of the Department of Defense Congressionally Directed Medical Research Program, which has broadened to 34 other diseases with an FY24 budget of $1.5 billion.
